Those rates were similar against best available therapy -- hydroxyurea, chemotherapy agents, or corticosteroids. None of those shrank spleens by at least 35% in any patient in the COMFORT-II trial, Claire Harrison, DM, of Guy's Hospital in London, and colleagues found.